NO20042833L - Vaksine og fremgangsmate for behandling av motorneuronale lidelser - Google Patents

Vaksine og fremgangsmate for behandling av motorneuronale lidelser

Info

Publication number: NO20042833L
Authority: NO; Norway
Prior art keywords: cop; vaccine; neuronal disorders; treating motor; tyr
Prior art date: 2001-12-06

Application number

NO20042833A

Other languages

English (en)

Other versions

NO336231B1 (no

Inventor

Michal Eisenbach-Schwartz

Esther Yoles

Original Assignee

Yeda Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-06

Filing date

2004-07-05

Publication date

2004-08-12

2004-07-05 Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev

2004-08-12 Publication of NO20042833L publication Critical patent/NO20042833L/no

2015-06-22 Publication of NO336231B1 publication Critical patent/NO336231B1/no

Links

229960005486 vaccine Drugs 0.000 title abstract 2
230000001537 neural effect Effects 0.000 title 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 3
208000026072 Motor neurone disease Diseases 0.000 abstract 2
239000013543 active substance Substances 0.000 abstract 2
206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
206010061818 Disease progression Diseases 0.000 abstract 1
206010056677 Nerve degeneration Diseases 0.000 abstract 1
239000002671 adjuvant Substances 0.000 abstract 1
230000005750 disease progression Effects 0.000 abstract 1
229930195712 glutamate Natural products 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
230000001988 toxicity Effects 0.000 abstract 1
231100000419 toxicity Toxicity 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Mycology (AREA)
Microbiology (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Physical Education & Sports Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Orthopedic Medicine & Surgery (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)

NO20042833A 2001-12-06 2004-07-05 Anvendelse av Cop-1 for fremstilling av en vaksine for behandling av amyotrofisk lateral sklerose (ALS). NO336231B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33613901P	2001-12-06	2001-12-06
PCT/IL2002/000979 WO2003047500A2 (en)	2001-12-06	2002-12-05	Vaccine and method for treatment of motor neurone diseases

Publications (2)

Publication Number	Publication Date
NO20042833L true NO20042833L (no)	2004-08-12
NO336231B1 NO336231B1 (no)	2015-06-22

Family

ID=23314742

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20042833A NO336231B1 (no)	2001-12-06	2004-07-05	Anvendelse av Cop-1 for fremstilling av en vaksine for behandling av amyotrofisk lateral sklerose (ALS).

Country Status (23)

Country	Link
US (1)	US7351686B2 (no)
EP (1)	EP1429800B1 (no)
JP (1)	JP4542339B2 (no)
KR (1)	KR20040081431A (no)
CN (2)	CN1617736A (no)
AT (1)	ATE422362T1 (no)
AU (1)	AU2002353486B2 (no)
CA (1)	CA2469092C (no)
CY (1)	CY1109044T1 (no)
DE (1)	DE60231131D1 (no)
DK (1)	DK1429800T3 (no)
ES (1)	ES2322566T3 (no)
HU (1)	HU228207B1 (no)
IL (1)	IL160105A0 (no)
IS (1)	IS2670B (no)
MX (1)	MXPA04005537A (no)
NO (1)	NO336231B1 (no)
NZ (1)	NZ533356A (no)
PL (1)	PL205469B1 (no)
PT (1)	PT1429800E (no)
RU (1)	RU2303996C2 (no)
SI (1)	SI1429800T1 (no)
WO (1)	WO2003047500A2 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7399740B2 (en)	2001-06-28	2008-07-15	Yeda Research And Development Co. Ltd.	Poly-Glu,Tyr for neuroprotective therapy
WO2004060265A2 (en) *	2003-01-07	2004-07-22	Yeda Research And Development Co. Ltd.	Eye-drop vaccine containing copolymer 1 for therapeutic immunization
CA2546077C (en)	2003-11-12	2016-07-05	Yeda Research And Development Co. Ltd.	Vaccine and method for treatment of neurodegenerative diseases
DK1701730T3 (da)	2003-12-09	2013-11-25	Yeda Res & Dev	Fremgangsmåde og vaccine omfattende copolymer 1 til behandling af psykiatriske forstyrrelser
EP1778286A4 (en) *	2004-03-03	2009-04-08	Teva Pharma	COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
US7655221B2 (en)	2004-05-07	2010-02-02	Peptimmune, Inc.	Methods of treating disease with random copolymers
CA2565819A1 (en) *	2004-05-07	2005-12-01	Peptimmune, Inc.	Methods of treating disease with random copolymers
JP5241012B2 (ja) *	2005-07-15	2013-07-17	ノバルティスアーゲー	Ｐａｍｐｓ、病原体関連分子パターン
CN100448481C (zh) *	2006-06-22	2009-01-07	中国科学院遗传与发育生物学研究所	xCT蛋白及其编码基因的新用途
WO2009040814A1 (en)	2007-09-24	2009-04-02	Hadasit Medical Research Services & Development Ltd	Use of copolymer 1 for treatment of muscular dystrophy
USRE49251E1 (en)	2010-01-04	2022-10-18	Mapi Pharma Ltd.	Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) *	2010-03-16	2014-06-24	Teva Pharmaceutical Industries, Ltd.	Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
EA025780B1 (ru)	2010-10-11	2017-01-30	Тева Фармасьютикал Индастриз Лтд.	Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
ES2601892T3 (es)	2011-04-21	2017-02-16	Mapi Pharma Limited	Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
MX2014004309A (es)	2011-10-10	2015-07-06	Teva Pharma	Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer.
US9861686B2 (en) *	2011-12-05	2018-01-09	Ben-Gurion University Of The Negev Research & Development Authority	Diagnostic and therapeutic methods and their application in amyotrophic lateral sclerosis (ALS)
KR20140145173A (ko) *	2012-03-26	2014-12-22	예다 리서치 앤드 디벨럽먼트 캄파니 리미티드	알츠하이머 질병 진단 및 알츠하이머 질병 진행 진단용 세포 마커
EP2892353A4 (en)	2012-09-10	2016-10-26	Yeda Res & Dev	INDIVIDUALIZED IMMUNOMODULATION THERAPY FOR NEURODEGENERATIVE ILLNESSES, CNS LESIONS AND AGGREGATIVE DEMENTIA
US12097292B2 (en)	2016-08-28	2024-09-24	Mapi Pharma Ltd.	Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en)	2016-08-31	2024-09-05	Mapi Pharma Ltd	Depot systems comprising glatiramer acetate
IL316573A (en)	2017-03-26	2024-12-01	Mapi Pharma Ltd	Storage systems containing glatiramer acetate for the treatment of multiple sclerosis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL36670A (en) *	1971-04-21	1974-09-10	Sela M	Therapeutic basic copolymers of amino acids
US3849650A (en)	1973-03-29	1974-11-19	Picker Corp	Automatic x-ray inspection system
IL113812A (en)	1994-05-24	2000-06-29	Yeda Res & Dev	Copolymer-1 pharmaceutical compositions containing it and its use
SE505316C2 (sv) *	1995-10-17	1997-08-04	Kenneth G Haglid	Användning av proteinet S-100b för framställning av läkemedel för nervceller
RU2211697C2 (ru) *	1996-09-27	2003-09-10	Гилфорд Фармасьютикалз Инк.	Способ лечения глутаматных расстройств
JP2002503658A (ja) *	1998-02-13	2002-02-05	オートイミューンインク	ＣＯＰ−１及びＴｈ−２促進性サイトカインを使用した、多発性硬化症の治療
US20030108528A1 (en)	1998-05-19	2003-06-12	Michal Eisenbach-Schwartz	Activated t-cells, nervous system-specific antigens and their uses
US20020072493A1 (en)	1998-05-19	2002-06-13	Yeda Research And Development Co. Ltd.	Activated T cells, nervous system-specific antigens and their uses
WO1999060021A2 (en)	1998-05-19	1999-11-25	Yeda Research And Development Co. Ltd.	Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
EP1039929A1 (en)	1998-07-21	2000-10-04	YEDA RESEARCH AND DEVELOPMENT Co. Ltd.	Activated t-cells and their uses
JP2003521448A (ja)	1998-07-23	2003-07-15	ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ	合成ペプチドおよび自己免疫疾患治療のための使用方法
RU2155063C1 (ru) *	1999-10-20	2000-08-27	Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии"	Тетрапептид, стимулирующий функциональную активность нейронов, фармакологическое средство на его основе и способ его применения
HK1054507B (zh) *	2000-01-20	2008-10-31	耶达研究及发展有限公司	共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途
DE60116467T2 (de)	2000-06-07	2006-11-02	Yeda Research And Development Co., Ltd.	Verwendung des Copolymer-1 Peptids sowie von damit verwandten Peptiden und Polypeptiden und von damit behandelten T-Zellen zur Neuroprotektion gegen die Toxizität von Glutamat
WO2002076503A1 (en) *	2000-06-20	2002-10-03	Mayo Foundation For Medical Education And Research	Treatment of central nervous system diseases by antibodies against glatiramer acetate
US6835711B2 (en) *	2001-06-28	2004-12-28	Yeda Research And Development Co. Ltd.	Use of poly-Glu,Tyr for neuroprotective therapy
US7399740B2 (en) *	2001-06-28	2008-07-15	Yeda Research And Development Co. Ltd.	Poly-Glu,Tyr for neuroprotective therapy

2002
- 2002-12-05 US US10/485,576 patent/US7351686B2/en not_active Expired - Lifetime
- 2002-12-05 EP EP02788511A patent/EP1429800B1/en not_active Expired - Lifetime
- 2002-12-05 HU HU0500039A patent/HU228207B1/hu not_active IP Right Cessation
- 2002-12-05 DE DE60231131T patent/DE60231131D1/de not_active Expired - Lifetime
- 2002-12-05 KR KR10-2004-7008780A patent/KR20040081431A/ko not_active Ceased
- 2002-12-05 DK DK02788511T patent/DK1429800T3/da active
- 2002-12-05 AU AU2002353486A patent/AU2002353486B2/en not_active Ceased
- 2002-12-05 PL PL370070A patent/PL205469B1/pl unknown
- 2002-12-05 WO PCT/IL2002/000979 patent/WO2003047500A2/en not_active Ceased
- 2002-12-05 JP JP2003548761A patent/JP4542339B2/ja not_active Expired - Fee Related
- 2002-12-05 SI SI200230800T patent/SI1429800T1/sl unknown
- 2002-12-05 CN CNA028277015A patent/CN1617736A/zh active Pending
- 2002-12-05 RU RU2004120536/14A patent/RU2303996C2/ru not_active IP Right Cessation
- 2002-12-05 CN CN201110056639.8A patent/CN102151330B/zh not_active Expired - Fee Related
- 2002-12-05 AT AT02788511T patent/ATE422362T1/de active
- 2002-12-05 NZ NZ533356A patent/NZ533356A/en not_active IP Right Cessation
- 2002-12-05 MX MXPA04005537A patent/MXPA04005537A/es active IP Right Grant
- 2002-12-05 IL IL16010502A patent/IL160105A0/xx unknown
- 2002-12-05 CA CA2469092A patent/CA2469092C/en not_active Expired - Fee Related
- 2002-12-05 PT PT02788511T patent/PT1429800E/pt unknown
- 2002-12-05 ES ES02788511T patent/ES2322566T3/es not_active Expired - Lifetime
2004
- 2004-06-03 IS IS7296A patent/IS2670B/is unknown
- 2004-07-05 NO NO20042833A patent/NO336231B1/no not_active IP Right Cessation
2009
- 2009-05-06 CY CY20091100485T patent/CY1109044T1/el unknown

Also Published As

Publication number	Publication date
WO2003047500A2 (en)	2003-06-12
AU2002353486B2 (en)	2009-01-15
EP1429800A2 (en)	2004-06-23
PL370070A1 (en)	2005-05-16
HK1067043A1 (en)	2005-04-01
IS2670B (is)	2010-09-15
CN102151330A (zh)	2011-08-17
IL160105A0 (en)	2004-06-20
DK1429800T3 (da)	2009-04-27
HUP0500039A2 (hu)	2005-03-29
SI1429800T1 (sl)	2009-08-31
ATE422362T1 (de)	2009-02-15
NZ533356A (en)	2006-10-27
JP4542339B2 (ja)	2010-09-15
ES2322566T3 (es)	2009-06-23
HU228207B1 (hu)	2013-01-28
CA2469092A1 (en)	2003-06-12
NO336231B1 (no)	2015-06-22
PT1429800E (pt)	2009-04-27
US7351686B2 (en)	2008-04-01
IS7296A (is)	2004-06-03
KR20040081431A (ko)	2004-09-21
CY1109044T1 (el)	2014-07-02
MXPA04005537A (es)	2004-11-01
DE60231131D1 (de)	2009-03-26
CA2469092C (en)	2013-02-19
RU2303996C2 (ru)	2007-08-10
US20050220802A1 (en)	2005-10-06
EP1429800B1 (en)	2009-02-11
CN1617736A (zh)	2005-05-18
EP1429800A4 (en)	2006-03-22
RU2004120536A (ru)	2005-03-27
AU2002353486A1 (en)	2003-06-17
WO2003047500A3 (en)	2004-03-18
CN102151330B (zh)	2017-04-12
HUP0500039A3 (en)	2010-01-28
PL205469B1 (pl)	2010-04-30
JP2005515198A (ja)	2005-05-26

Legal Events

Date	Code	Title	Description
2021-07-26	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
EP1429800A4 (en)	2006-03-22	VACCINE AND METHOD FOR THE TREATMENT OF MOTOR NEURONAL DISEASES
EA200601132A1 (ru)	2007-02-27	Предупреждение и лечение амилоидогенного заболевания
AU1879697A (en)	1997-09-16	Peptide immunogens for vaccination against and treatment of allergy
WO2002100390A3 (en)	2004-04-22	Improved method of treating the syndrome of coronary heart disease risk factors in humans
ATE306931T1 (de)	2005-11-15	Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
WO1994008551A3 (en)	1994-06-23	Pharmaceutical compositions and methods for treating cold symptoms
EP1040830A4 (en)	2002-10-23	MEDICINE FOR NEURODEGENERATIVE DISEASES
BG105575A (en)	2002-01-31	Method and agent for the treatment of cerebral ischaemia
EP2279742A3 (en)	2011-04-20	Combinations for the treatment of immunoinflammatory disorders
MY118526A (en)	2004-11-30	Method for improving the pharmacokinetics of tipranavir
BR9610679A (pt)	1999-03-30	Antígenos de leishmania para uso na terapia e disgnose da leishmaniose
NZ516477A (en)	2004-02-27	Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
SE9603725D0 (sv)	1996-10-11	New teatment
MX9707642A (es)	1997-12-31	Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
AU2001267864A1 (en)	2002-01-08	Remedial agent for optic nerve disease and the like
JO3446B1 (ar)	2020-07-05	طريقة لمعالجة الأرق الأولي
EP0744176A3 (en)	2002-05-15	Methods for inhibiting bone loss
MXPA02011533A (es)	2003-04-25	Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
NZ505538A (en)	2004-12-24	A vaccine comprising immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide (PIM); and the use of PIM for inducing an immune response in a patient effective in the prevention or treatment of Th2-mediated diseases or disorders such as asthma
WO2002058532A3 (en)	2002-11-21	Method for identifying ligands to lxr-receptor that stimulates pre-adipocyte differentiation and formulations thereof
DE60223564D1 (de)	2007-12-27	Therapeutische impfzusammensetzung zur verhütung und behandlung von erkrankungen bei säugetieren
WO2004034062A3 (en)	2004-06-03	Use of cap-1 for the therapy of asthma
WO2003045322A3 (en)	2004-01-22	Method for treating and preventing pancreatitis
TW200501958A (en)	2005-01-16	A therapeutic agent for treating a behavioral disorder
GR3035004T3 (en)	2001-03-30	Method and composition for the treatment of herpes related disorders.